Coherus BioSciences

Redwood City,  CA 
United States
https://www.coherus.com/

• Booth: 5031a

Coherus BioSciences is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that can expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA® (pegfilgrastim-cbqv). Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® in the United States and through 2023 expects to launch biosimilars of Humira®, Avastin® and Lucentis®, if approved.

Brands: https://events.jspargo.com/ASCO21/CUSTOM/Coherus_SocialMedia_Banners_LinkedIn.jpg

 Show Specials

• UDENYCA® (pegfilgrastim-cbqv) Video (May 10, 2021)
  https://www.youtube.com/watch?v=mTEt7W6g2bc

 Press Releases

• C. UDENYCA® (pegfilgrastim-cbqv) Website (Apr 27, 2021)
  https://www.udenyca.com

• E. Toripalimab Program (Apr 27, 2021)
  https://www.coherus.com/immuno-oncology/toripalimab-program

• D. Coherus COMPLETE™ Overview Brochure (Apr 27, 2021)
  https://events.jspargo.com/ASCO21/CUSTOM/Coherus%20COMPLETE%20Overview%20Brochure.pdf

• A. UDENYCA® (pegfilgrastim-cbqv) Healthcare Professional Brochure (Apr 27, 2021)
  https://events.jspargo.com/ASCO21/CUSTOM/UDENYCA%20HCP%20Leave%20Behind.pdf

• B. UDENYCA® (pegfilgrastim-cbqv) Full Prescribing Information (Jun 02, 2021)
  https://biogenericsinc-my.sharepoint.com/:b:/g/personal/rkelmar_coherus_com/ERovu3FMsn9JiAsxbIDglawBn7f9sxWk6SnU8hnOMw0yww?e=U9BHEC

 Products